Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
5-Amino-1-methylquinolinium iodide is the lead first-in-class small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) an enzyme overexpressed in white adipose tissue of obese individuals where it consumes the methyl-donor pool and depletes tissue NAD
View Article 2
Results are remarkably consistent across participants, with 87% of those who complete treatment achieving at least 15% weight loss
Over time, stress, aging, and illness can disrupt this intricate messaging system
EU research contract GAP-2014-655232
(Switzerland) Altimmune (US) Glenmark Pharmaceuticals Ltd (India) Biocon (India) Teva Pharmaceuticals (Israel) MARKET SCOPE WHAT IS IN IT FOR YOU: GLP-1 Agonists Market REPORT CONTENT GUIDE DELIVERED CUSTOMIZATIONS We have successfully delivered the following deep-dive customizations: RECENT DEVELOPMENTS September 2025 : Novo Nordisk (Denmark) received EU approval for its oral GLP-1 receptor agonist drug, Rybelsus, to reduce cardiovascular death, heart attack, and stroke
US$ 20.59
US$ 24.75
US$ 23.21
US$ 25.02
